Genescience Pharmaceuticals Co. Ltd. has identified fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, osteochondrodysplasia and achondroplasia.
Genescience Pharmaceuticals Co. Ltd. has identified phosphatidylinositol 3-kinase α (PI3Kα) inhibitors, particularly PI3Kα (H1047R mutant), reported to be useful for the treatment of cancer and PIK3CA-related overgrowth spectrum.
Camptothecin derivatives reported to be useful for the treatment of cancer have been disclosed in a recent Genescience Pharmaceuticals Co. Ltd. patent.
Genescience Pharmaceuticals Co. Ltd. has identified melanocortin MC4 receptor antagonists reported to be useful for the treatment of cachexia, anorexia nervosa, nausea and vomiting, sarcopenia, neuropathic pain, post-traumatic stress disorder and muscle and bone disorders.
Genescience Pharmaceuticals Co. Ltd. has described fused ring kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Genescience Pharmaceuticals Co. Ltd. has divulged MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of rheumatoid arthritis and radiographic axial spondyloarthritis (ankylosing spondylitis).
Genescience Pharmaceuticals Co. Ltd. has described cannabinoid CB2 receptor agonists reported to be useful for the treatment of arthritis, systemic lupus erythematosus, inflammatory bowel disease, allergic contact dermatitis, colitis, autoimmune diseases and pain.
Genescience Pharmaceuticals Co. Ltd. has divulged indoline-containing spiro derivatives acting as growth hormone secretagogue receptor (GHSR) agonists reported to be useful for the treatment of growth hormone deficiency.
